Uforia MIT+13OH Chewable Tablets Blue Haze 80mg
Uforia MIT+13OH Chewable Tablets Blue Haze 80mg combine MIT and 13OH in a convenient chewable tablet format paired with a distinctive Blue Haze flavor. Featuring a clearly labeled 80mg strength, this specialty product is designed for experienced adult consumers familiar with concentrated alkaloid products and looking for an alternative to traditional powders, capsules, or liquid formats.
The MIT+13OH formula is the defining feature of this Uforia product, bringing two highlighted alkaloid components together in one easy-to-identify presentation. Clear 80mg labeling makes the product simple to distinguish when browsing different formulas and strengths within a specialty alkaloid collection.
The Blue Haze flavor adds a bold, flavor-forward element to the chewable format. Its distinctive profile provides an alternative for customers who prefer flavored products rather than unflavored capsules or naturally earthy traditional kratom formats. Combined with Uforia’s recognizable branding, Blue Haze gives this variety its own identity on the shelf or product page.
Convenience is another standout feature. The chewable tablet design eliminates the need for loose powder, measuring, mixing, or managing liquid extract bottles. Its compact format requires minimal storage space and provides a straightforward option for customers who prefer chewable products.
Uforia pairs concentrated alkaloid content with clear product identification, highlighting the MIT+13OH formula, Blue Haze flavor, chewable format, and 80mg labeled strength. This makes the exact variety easy to recognize and compare with other specialty products.
Concentrated alkaloid products can differ substantially from traditional kratom leaf products. Customers should carefully review the complete package label to verify what the stated 80mg represents, along with the full ingredients, manufacturer directions, serving information, age requirements, and applicable warnings before use. Store securely and away from children.
